Press Releases April 16, 2026 08:00 PM

Sysco Declares Increase to Quarterly Dividend Payment

Sysco Announces Quarterly Dividend Increase Reflecting Commitment to Shareholder Returns

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SYY

Sysco Corporation's Board of Directors declared a quarterly cash dividend increase of $0.01 to $0.55 per share, payable July 24, 2026. This dividend raise highlights Sysco's strong shareholder return strategy and its status as a Dividend Aristocrat. The company plans a total annual dividend increase of $0.04 for fiscal year 2027, reinforcing its balanced capital allocation approach.

Sysco Declares Increase to Quarterly Dividend Payment
SYY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Sysco raised its quarterly dividend to $0.55 per share, up $0.01 from the previous quarter.
  • The dividend increase demonstrates Sysco's commitment to consistent shareholder returns and maintaining Dividend Aristocrat status.
  • Sysco operates in the foodservice distribution sector with broad coverage of restaurants, healthcare, education, and lodging industries, impacting supply chain and food distribution markets.

HOUSTON, April 17, 2026 (GLOBE NEWSWIRE) -- Sysco Corporation (NYSE:SYY) today announced that its Board of Directors declared a quarterly cash dividend of $0.55 per share, representing a $0.01 increase from the prior quarterly dividend of $0.54 per share. The new dividend is payable for the first time on July 24, 2026, to common stockholders of record at the close of business on July 2, 2026.

“The Board’s decision today to increase the dividend underscores Sysco's commitment to delivering consistent shareholder returns, maintaining our status as a Dividend Aristocrat, and executing a disciplined, balanced approach to capital allocation. Our decision today further rewards our shareholders with a planned annual dividend increase of $0.04 for fiscal year 2027,” said Brandon Sewell, Sysco’s interim chief financial officer.

About Sysco

Sysco is the global leader in selling, marketing and distributing food and related products to customers who prepare meals away from home. This includes restaurants, healthcare and educational facilities, lodging establishments, entertainment venues, and more. Sysco operates 337 distribution centers, in 10 countries, with 75,000 colleagues serving approximately 730,000 customer locations. The company generated sales of more than $81 billion in fiscal year 2025 that ended June 28, 2025.

As the world’s largest food-away-from-home distributor, Sysco offers customized supply chain solutions, bespoke specialty product offerings, and culinary support to drive customers to innovate and optimize their operations. We act as a trusted business partner to our customers, helping them grow through our industry-leading portfolio that includes fresh produce, premium proteins, specialty products, sustainably focused items, equipment and supplies, and innovative culinary solutions.

For more information, visit www.sysco.com. For important news and key information for Sysco investors, visit the Investor Relations section of the company’s website at investors.sysco.com.

For more information contact:

Kevin Kim
Investor Contact
[email protected]
T 281-584-1219


Cassandra Mauel
Media Contact
[email protected]
T 281-584-1390


SYY-INVESTORS


Risks

  • Dividend increases depend on continued strong cash flow and profitability; economic downturns or disruptions in the foodservice industry could pressure future payouts.
  • Supply chain challenges or increased costs in food and related product distribution could impact Sysco's financial performance.
  • Competition and changing customer demands within foodservice distribution could affect growth and dividend sustainability.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026